Document 0096
 DOCN  M94A0096
 TI    Fluconazole therapy of oral candidiasis in HIV-infected patients:
       results of a multicentre study.
 DT    9412
 AU    Plettenberg A; Stoehr A; Hoffken G; Bergs C; Tschechne B; Ruhnke M;
       Heise W; Dieckmann S; Meigel W; Abteilung fur Dermatologie, Medizinische
       Klinik, Hamburg,; Germany.
 SO    Infection. 1994 Mar-Apr;22(2):118-23. Unique Identifier : AIDSLINE
       MED/94350500
 AB    In an open phase-III study 103 HIV-positive patients with oral
       candidiasis were treated with oral fluconazole 100 mg/day for 7-21 days
       (mean 12.2 +/- 6.1 days). Ninety per cent of the patients presented with
       the full clinical picture of AIDS, in 83% CD4-lymphocytes were <
       100/mm3. Clinical and mycological (smear and mouth rinsing) examinations
       were performed at the start of therapy, after weeks 1, 2, and 3, and at
       the end of therapy. The clinical findings showed fluconazole therapy to
       have achieved cure in 71% of the patients and improvement in 16%.
       Therapy failed in 13%. Mycological tests revealed elimination in 57% and
       reduction in colony counts in 23% of patients. Therapy failure according
       to mycological criteria was observed in 20% of all subjects. Adverse
       events were recorded for 26% of all patients. A causal connection with
       study therapy was considered as unlikely in 20 cases, questionable in 17
       cases, and likely in three cases. Premature discontinuation of
       fluconazole therapy was required in seven patients, in three of them
       because of adverse events due to fluconazole. Even in patients with
       advanced HIV infection and consequently severe immunodeficiency,
       fluconazole is an important improvement of the therapeutic spectrum.
 DE    Administration, Oral  Adult  AIDS-Related Opportunistic
       Infections/BLOOD/DIAGNOSIS/*DRUG  THERAPY  Candidiasis,
       Oral/BLOOD/DIAGNOSIS/*DRUG THERAPY  Female  Fluconazole/*THERAPEUTIC USE
       Human  Leukocyte Count  Male  Middle Age  Severity of Illness Index
       Treatment Failure  T4 Lymphocytes  CLINICAL TRIAL  CLINICAL TRIAL, PHASE
       III  JOURNAL ARTICLE  MULTICENTER STUDY

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).